View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 16, 2020

Germany to invest €300m in CureVac’s mRNA platform technology

The German Federal Government is set to invest €300m in CureVac, a biotechnology company focused on using messenger RNA (mRNA) technology to develop drugs and vaccines.

The German Federal Government is set to invest €300m in CureVac, a biotechnology company focused on using messenger RNA (mRNA) technology to develop drugs and vaccines.

Free Report
img

How attractive are current investment opportunities in Europe?

Europe has been identified as one of the most favorable regions for investors, seeing high investment activity in the past year. Most of these investments have been through Debt Offering, valued at close to $700 billion. The region has provided attractive investments in a diverse set of companies. Companies who tend to major themes such Digital Media, Cloud, Artificial Intelligence, E-commerce, and Big Data are recording the highest number of deals, with Digital Media recording close to 2,000 deals. However, GlobalData’s whitepaper offers a full view of the market, analyzing less successful or attractive points of investment as well, examining statistics on Equity Offering investments and PE/VC deals. Understand how government agencies for economies around the world use GlobalData Explorer to:  
  • Track the M&A and Capital Raising volumes into their target market
  • Identify the top sectors in the target market attracting the investments
  • For any investment segment, identify the top Investors inside and outside the target economy that are already investing in the Segment
  • Assess and showcase the growth potential for various Industries in the target economy
Don’t miss out on key market insights that can help optimize your next investment – read the report now.
by GlobalData
Enter your details here to receive your free Report.

Germany will make the investment through Kreditanstalt für Wiederaufbau and is supported by investment company dievini Hopp BioTech, a major shareholder in CureVac.

The company intends to use the funds to further develop its mRNA platform technology and pipeline, as well as to expand its business.

The German government expects the investment to speed-up CureVac’s development programmes and help the company advance its technology.

Speaking of the development, German Federal Minister for Economic Affairs and Energy Peter Altmaier said: “CureVac’s technology has the potential to develop disruptive new vaccines and therapeutic modalities that are accessible for many people and available via the market.

“At the same time, today’s move is a first and important implementation of the comprehensive Corona Economic Stimulus and Future Technologies Package, which was agreed on by the Federal Government on 3 June 2020. With this package, we aim to secure more independence in the entire production process of medical substances and vaccines.”

The deal will provide Kreditanstalt für Wiederaufbau with approximately 23% stake in the company, which will retain complete operational and strategic independence.

CureVac acting CEO and chief operating officer Dr Franz-Werner Haas said: “This strong financial commitment provides us further cash reach and stability for the accelerated development of our mRNA platform, the development and production of our current and additional mRNA vaccine and drug candidates, as well as the strategic expansion of our organisation.”

In March, CureVac announced that the company is developing an mRNA-based vaccine to protect against Covid-19. The company noted that mRNA’s mechanism of action makes it a potent molecule for a quick and efficient solution in case of outbreaks, such as the novel coronavirus pandemic.

Related Companies

Free Report
img

How attractive are current investment opportunities in Europe?

Europe has been identified as one of the most favorable regions for investors, seeing high investment activity in the past year. Most of these investments have been through Debt Offering, valued at close to $700 billion. The region has provided attractive investments in a diverse set of companies. Companies who tend to major themes such Digital Media, Cloud, Artificial Intelligence, E-commerce, and Big Data are recording the highest number of deals, with Digital Media recording close to 2,000 deals. However, GlobalData’s whitepaper offers a full view of the market, analyzing less successful or attractive points of investment as well, examining statistics on Equity Offering investments and PE/VC deals. Understand how government agencies for economies around the world use GlobalData Explorer to:  
  • Track the M&A and Capital Raising volumes into their target market
  • Identify the top sectors in the target market attracting the investments
  • For any investment segment, identify the top Investors inside and outside the target economy that are already investing in the Segment
  • Assess and showcase the growth potential for various Industries in the target economy
Don’t miss out on key market insights that can help optimize your next investment – read the report now.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology